CytoMed Therapeutics' LongevityBank Secures A Non-Dilutive Investment From ICH Capital Of Up To $500K

CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced today that it secures non-dilutive investment for its subsidiary, LongevityBank Pte Ltd ("LongevityBank") from ICH Capital Pte Ltd ("ICH Capital").

Following the announcement dated August 28, 2025, the strategic vision is for LongevityBank to focus on autologous (using one's own blood, cells and/or tissues) therapies leveraging its personalized cellular banking services while parent company, CytoMed focuses on donor blood-derived allogeneic (using donated blood, cells and/or tissues) therapies which already has an approved IND Phase I clinical trial ongoing in Singapore and a Phase II Investigator-Initiated Trial (IIT) in India. Allogeneic therapies have the advantage of treatment speed, accessibility and cost-effectiveness. Autologous therapies are less likely to be rejected by one's own immune system and are better tolerated with higher acceptance level by the immune systems of patients albeit more costly than allogeneic therapies.

CytoMed is pleased to announce ICH Capital has agreed to invest up to US$500,000 for a 10.0% post-money stake in LongevityBank. Founded in 2001, ICH Capital is a well-known Singapore-based investment firm that provides cross-border wealth and asset management solutions for ultra-high net worth individuals and institutions across Asia-Pacific.